NEW YORK – Oncocyte said on Wednesday that it has reached definitive agreements with its two largest institutional investors, Pura Vida Investments and Broadwood Partners, to purchase $25 million of the company's common shares in a registered offering.
The firm anticipates selling 7,301,402 shares of its common stock at a price of $3.42 per share, the average of the stock's last five closing prices.